Premium
Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma
Author(s) -
Lewenhaupt Arvid,
Ekman Peter,
Eneroth Peter,
Nilsson Bo,
Nordstrom Lennart
Publication year - 1985
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990060308
Subject(s) - medicine , prostatic acid phosphatase , antigen , carcinoma , stage (stratigraphy) , prostate specific antigen , multivariate analysis , prostatic adenocarcinoma , adenocarcinoma , acid phosphatase , oncology , pathology , prostate , urology , gastroenterology , cancer , immunology , biology , enzyme , paleontology , biochemistry
Serum levels of tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in serum, the presence or absence of skeletal metastases, tumor grade, patient age, and erythrocyte sedimentation rate (ESR) were determined in 50 patients with prostatic adenocarcinoma before onset of any therapy. Crude survival rates were estimated for a 5‐year period after the time of diagnosis. The prognostic value was estimated by means of the log rank test and multivariate life table analysis. The TPA, PAP, tumor stage, and ESR all appeared to be useful as prognostic markers. Tumor grade and patient age were not significantly related to crude survival. The TPA proved to be the most reliable prognostic marker in single test estimates as well as in a multivariate life table analysis (p < 0.01).